EPISODE · Sep 1, 2020 · 12 MIN

Prof. Hiddo Heerspink: Insights from DAPA-CKD

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink. Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology examining the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use of dapagliflozin in patients with and without type 2 diabetes.

Episode metadata supplied by the publisher feed · Published Sep 1, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

Prof. Hiddo Heerspink: Insights from DAPA-CKD

0:00 12:11

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 12 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on September 1, 2020.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!